Davis noted, “We believe Lipocine’s LPCN 1021 has overcome these barriers because: 1) it met FDA-guided Phase 3 endpoints; 2) it has convenient twice-daily oral pill dosing; 3) a very clean safety profile; and 4) minimal food effects.”
Moreover, “With the potential to have the first and only oral TRT in the market, we think Lipocine would be an ideal target for a company like Endo, with a declining urology franchise looking for differentiated products. We generally don’t put much emphasis on early-stage drug candidates, but we think ‘1107 is an exception and would make an excellent complement to something like AMAG’s Makena for example. 1107 is an oral hydroxyprogesterone for preventing pre-term birth in women with prior cases.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Corey Davis has a total average return of 19.5% and a 62.5% success rate. Davis is ranked #201 out of 3640 analysts.
With a return potential of 67.5%, the stock’s consensus target price stands at $13.50.